GSK Plans to Open Patient-Level Trial Data to Outside Researchers

GlaxoSmithKline will soon give researchers access to detailed anonymized patient-level clinical data for approved drugs and dropped investigational products. The move could force other pharma companies to follow suit, one expert says. Under the plan, researchers will be able to examine data more closely, or combine data from different studies, to further future research. This could include learning how drugs work in different populations.
Clinical Trials Advisor